This article is more than 5 years old. Information may no longer be current.

Biomet announces acquisition of substantially all of the assets of Cytosol Laboratories, Inc.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Biomet, Inc., announced in a press release the acquisition of substantially all of the assets of Cytosol Laboratories, Inc., a market leader in production of small volume anticoagulants.

Cytosol was founded in 1968 to develop anticoagulants and other products to aid in the processing of blood components. According to the press release, the company has three proprietary products with New Drug Application approvals: TriCitrasol, noClot-50 and Rejuvesol. TriCitrasol is used for anticoagulation during granulocytapheresis while Rejuvesol is used for the rejuvenation of stored, frozen red blood cells prior to transfusion.

“This acquisition solidifies a critical supply component utilized by our market-leading GPS III Platelet Separation System and BioCue Platelet Concentration System for concentrating a mixture of blood and bone marrow,” Stuart Kleopfer, president of Biomet Biologics, stated. “In addition, given the increased scrutiny of stored red blood cells and increasing attention being paid by clinicians to the benefits of granulocytapheresis, both of these products have excellent market potential. We welcome the Cytosol team and are eager to explore additional indications for this unique product line.”